Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 887 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Climara Clear all
Completed Phase 2 Interventional Results available

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

NCT03056755
View directory record Official record
Conditions
Breast Cancer
Interventions
Alpelisib, Fulvestrant, Letrozole, Goserelin, Leuprolide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
25
States / cities
Gilbert, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 25, 2026, 5:01 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Advancing Postmenopausal Preventive Therapy

NCT04103476
View directory record Official record
Conditions
Atherosclerosis, Cognitive Decline
Interventions
Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg, Placebo
Combination Product · Other
Lead sponsor
University of Southern California
Other
Eligibility
45 Years to 59 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 25, 2026, 5:01 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Application for the Etonogestrel/Ethinyl Estradiol Ring

NCT03120728
View directory record Official record
Conditions
Emergency Contraception, Healthy, Reproductive Age Women
Interventions
Etonogestrel/ethinyl estradiol contraceptive vaginal ring
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 25, 2026, 5:01 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

NCT03584009
View directory record Official record
Conditions
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
Interventions
Venetoclax, Fulvestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
21
States / cities
Phoenix, Arizona • Springdale, Arkansas • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 25, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Potential Drug Interaction Of Bazedoxifene & Premarin In Healthy Postmenopausal Women

NCT00706225
View directory record Official record
Conditions
Postmenopause
Interventions
Bazedoxifene and conjugated estrogens
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2010 · Synced Oct 25, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen

NCT03324685
View directory record Official record
Conditions
Drug Interactions
Interventions
BIIB074, OC (ethinyl estradiol and levonorgestrel)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 25, 2026, 5:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Stress, Sex, and the Generalization of Fear

NCT03786952
View directory record Official record
Conditions
Psychological Stress
Interventions
Stress immediately before learning in males, Sham control immediately before learning in males, Stress 30 minutes before learning in males, Sham control 30 minutes before learning in males, Stress immediately before learning in females, Sham control immediately before learning in females, Stress 30 minutes before learning in females, Sham control 30 minutes before learning in females
Behavioral
Lead sponsor
Ohio Northern University
Other
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Ada, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 25, 2026, 5:01 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Myomectomy vs Uterine Artery Embolization vs GnRh Antagonist for AUB-L

NCT04856306
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Fibroid Uterus
Interventions
Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure, Elagolix Oral Product
Other · Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 25, 2026, 5:01 PM EDT
Terminated Phase 2 Interventional

Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer

NCT00206414
View directory record Official record
Conditions
BREAST CANCER
Interventions
Iressa Day 1 given with Arimidex and Faslodex, Iressa Day 21 given with Arimidex and Faslodex
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 25, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AZD6140 Oral Contraceptive Interaction Study

NCT00685906
View directory record Official record
Conditions
Healthy
Interventions
AZD6140, Levonorgestrel and Ethinyl Estradiol (Nordette®)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 2, 2010 · Synced Oct 25, 2026, 5:01 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain

NCT03343067
View directory record Official record
Conditions
Endometriosis
Interventions
elagolix, estradiol/norethindrone acetate (E2/NETA)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
37
States / cities
Anniston, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 25, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)

NCT00754065
View directory record Official record
Conditions
Contraception
Interventions
Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027), Ortho Tri Cyclen Lo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
34
States / cities
Independence, Arizona • Phoenix, Arizona • Encinitas, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 25, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Results available

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00028769
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, estramustine, etoposide, flutamide, goserelin, leuprolide, nilutamide, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
91
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 25, 2026, 5:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Relationship Between the Menstrual Cycle and Heart Disease in Women

NCT01546454
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
Ethinyl Estradiol-Levonorgestrel combination, leuprolide acetate, Estradiol, Progesterone
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 25, 2026, 5:01 PM EDT
Completed Phase 2 Interventional

Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate

NCT00151073
View directory record Official record
Conditions
Hormone-Refractory Prostate Cancer
Interventions
Zoledronic acid, Estramustine, Docetaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2015 · Synced Oct 25, 2026, 5:01 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

NCT06428396
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Belzutifan, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
14
States / cities
Goodyear, Arizona • Beverly Hills, California • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 25, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women

NCT00242710
View directory record Official record
Conditions
Endometrial Hyperplasia, Osteoporosis
Interventions
Bazedoxifene/Conjugated Estrogen, CE 0.45 mg/MPA 1.5mg, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,083 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Upland, California • Inverness, Florida • West Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2013 · Synced Oct 25, 2026, 5:01 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers

NCT06995482
View directory record Official record
Conditions
Healthy Postmenopausal Women
Interventions
KSHN001034, Fulvestrant
Drug
Lead sponsor
Kashiv BioSciences, LLC
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 25, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol

NCT01243580
View directory record Official record
Conditions
Healthy
Interventions
Ortho-Cyclen, AG200-15
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 25, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis

NCT01044498
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Ortho-Novum® 1/35
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 44 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
6
States / cities
Little Rock, Arkansas • Beverly Hills, California • Ormond Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2013 · Synced Oct 25, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Comparing Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women

NCT00319163
View directory record Official record
Conditions
Healthy
Interventions
levonorgestrel/ethinyl estradiol
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2009 · Synced Oct 25, 2026, 5:01 PM EDT
Terminated Phase 2 Interventional Results available

Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy

NCT06005610
View directory record Official record
Conditions
HIV I Infection
Interventions
Estradiol
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
14
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 25, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Estradiol-Receptor Blockade in Older Men and Women

NCT02271282
View directory record Official record
Conditions
Normal Healthy Volunteers
Interventions
Toremifene, Placebo, GHRH/Ghrelin combined Injection
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Oct 25, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

NCT03262740
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BMS-986195, Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
South Miami, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 25, 2026, 5:01 PM EDT